Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

148.13 +1.26 (+0.86%)
Streaming Delayed Price Updated: 11:54 AM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
News headline image
Dow Falls Over 200 Points; Deere Earnings Miss Estimates ↗
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 200 points on Friday. 
Via Benzinga
News headline image
Why Is Axsome Therapeutics (AXSM) Stock Up 30% Today? ↗
Biopharmaceutical company AXSM stock is getting a huge lift from news the FDA has approved its depression treatment. 
Via InvestorPlace
News headline image
Axsome's Depression Candidate Scores FDA Nod, Stock Surges To 52-High ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Axsome Shares Shoot Higher As FDA Approves Major Depressive Disorder Candidate ↗
The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics’ (NASDAQ: AXSM) lead asset AUVELITY (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of... 
Via Benzinga
News headline image
Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help ↗
Today's depression drugs don't fit many patients' needs. Biotech companies may change that. 
Via Investor's Business Daily
News headline image
Axsome Therapeutics: Q2 Earnings Insights ↗
  Axsome Therapeutics (NASDAQ:AXSM) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Analyst Ratings for Axsome Therapeutics ↗
Analysts have provided the following ratings for Axsome Therapeutics (NASDAQ:AXSM) within the last quarter: 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Axsome Therapeutics ↗
  Axsome Therapeutics (NASDAQ:AXSM) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
7 Small-Cap Growth Stocks With 1,000% Upside Potential ↗
Here're 7 small-cap growth stocks with 1,000% upside potential. ACLS, AXSM, GBT, GPRO, HCAT, SKLZ, and VERU can make great investments. 
Via InvestorPlace
News headline image
Biotech Investors: August's Key PDUFA Catalysts You Must Know ↗
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the... 
Via Benzinga
News headline image
Axsome Therapeutics Just Took Its Key Moving Averages — Here's Why ↗
The stock surged by double digits in early trading. 
Via Investor's Business Daily
News headline image
AXSOME THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
7 Biotech Stocks to Buy for Q3 ↗
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. 
Via InvestorPlace
News headline image
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
AXSOME DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Axsome Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
NASDAQ:AXSM Investor Notice: Deadline on July 12, 2022 in Lawsuit Against Axsome Therapeutics, Inc. ↗
San Diego, CA -- (SBWIRE) -- 07/08/2022 -- The Shareholders Foundation announced that a deadline is coming up on July 12, 2022 in the lawsuit filed for certain investors of Axsome Therapeutics, Inc.... 
Via SBWire
News headline image
Do You Have Biotech FOMO? It Might Be Time To Pay Attention To These Names ↗
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say. 
Via Investor's Business Daily
News headline image
Do You Have Biotech FOMO? Why Cogent, Arvinas And Others Are Flying ↗
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say. 
Via Investor's Business Daily
News headline image
ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses Over $100K to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
ROSEN, A LEADING NATIONAL FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder ↗
Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea... 
Via Benzinga
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027
Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent... 
Via FinancialNewsMedia
News headline image
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday ↗
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
News headline image
Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.